Delta 4, a digital drug discovery company focusing on the identification of new indications for existing drug compounds, has announced that it successfully closed a multi-million Euro Series A financing round. The additional funding was provided by a major European Family Office investing in the life sciences, technology and other industries. Delta 4 will use the funding to accelerate the growth of its business. Further details on this financing round were not provided.

In 2020, the company announced that it has identified promising drug compounds for the treatment of a rare kidney disease and COVID-19. In recent months, these compounds were readied for Phase 2 clinical development. Delta 4 will now expand its clinical scope and initiate discovery and development programmes in additional indications.

“We are excited that the milestones achieved in our current discovery and development programmes attracted an experienced investor in our field who will join our investor base”, said Kurt Herpel, CEO, Delta 4. “In recent months, Delta 4 has highlighted its capabilities as a drug discovery engine able to generate a short list of drug candidates just months after applying our proprietary drug discovery platform to a targeted disease. Overall, it took us less than a year from the start of the discovery programme to have the most promising candidate validated in vivo and readied for clinical development. Following this financing round we will swiftly move into additional disease areas to consistently add to our pipeline of drug compounds that we can partner with the pharmaceutical industry.”